Related Experiment Video

Updated: Jan 17, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K

Overcoming EGFR mutation resistance: Dual inhibition strategies using TKIs in non-small cell lung cancer therapy

Jeevitha Sivam1, Azhar Ariffin1, Ajantha Sinniah2

  • 1Department of Chemistry, Faculty of Science, Universiti Malaya, Malaysia.

European Journal of Medicinal Chemistry
|September 20, 2025
PubMed

Insights

Dual-target inhibitors offer a promising strategy to overcome drug resistance in Epidermal Growth Factor Receptor (EGFR) mutant non-small cell lung cancer (NSCLC). By targeting multiple pathways, these inhibitors enhance efficacy and reduce resistance for improved patient outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Epidermal Growth Factor Receptor (EGFR) is a key target for non-small cell lung cancer (NSCLC) therapies.
  • Third-generation EGFR inhibitors like osimertinib are current standards but face significant drug resistance.
  • Resistance arises from EGFR mutations and activation of parallel oncogenic pathways (MET, HER2, VEGFR-2, PI3K).

Purpose of the Study:

  • To review the development and potential of dual-target EGFR inhibitors for overcoming therapeutic limitations in NSCLC.
  • To discuss rational target combinations and scaffold designs for dual-target inhibitors.
  • To highlight the advantages of dual-targeting strategies in combating drug resistance.

Main Methods:

  • Literature review focusing on dual-target inhibitor strategies for EGFR-mutant NSCLC.
  • Analysis of target combinations and their rationale.
  • Examination of chemical scaffold designs and their impact on biological activity.

Main Results:

  • Dual-target inhibitors show promise in overcoming resistance mechanisms associated with EGFR-mutant NSCLC.
  • Specific target combinations and chemical scaffolds are crucial for efficacy.
  • Advantages include improved efficacy, potentially lower dosage, reduced toxicity, and decreased resistance development.

Conclusions:

  • Dual-target EGFR inhibitors represent a transformative approach to NSCLC treatment.
  • This strategy offers a more effective and durable solution against drug resistance.
  • Advancements in dual-targeting aim to improve clinical outcomes for NSCLC patients.
Keywords:
Dual inhibitorsEGFRNSCLCResistance mechanismsTKIs

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K